ArticleBMC pulmonary medicine2024
A nomogram for predicting lymphovascular invasion in lung adenocarcinoma: a retrospective study.
Article in BMC pulmonary medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroudLymphovascular invasion (LVI) was histological factor that was closely related to prognosis of lung adenocarcinoma (LAC).The primary aim was to investigate the value of a nomogram incorporating clinical and computed tomography (CT) factors to predict LVI in LAC, and validating the predictive efficacy of a clinical model for LVI in patients with lung adenocarcinoma with lesions ≤ 3 cm.
methodsA total of 450 patients with LAC were retrospectively enrolled. Clinical data and CT features were analyzed to identify independent predictors of LVI. A nomogram incorporating the independent predictors of LVI was built. The performance of the nomogram was evaluated by assessing its discriminative ability and clinical utility.We took 321 patients with tumours ≤ 3 cm in diameter to continue constructing the clinical prediction model, which was labelled subgroup clinical model.
resultsCarcinoembryonic antigen (CEA) level, maximum tumor diameter, spiculation, and vacuole sign were independent predictors of LVI. The LVI prediction nomogram showed good discrimination in the training set [area under the curve (AUC), 0.800] and the test set (AUC, 0.790), the subgroup clinical model also owned the stable predictive efficacy for preoperative prediction of LVI in lung adenocarcinoma patients, and both training and test set AUC reached 0.740.
conclusionsThe nomogram developed in this study could predict the risk of LVI in LAC patients, facilitate individualized risk-stratification, and help inform treatment decision-makin, and the subgroup clinical model also had good predictive performance for lung cancer patients with lesion ≤ 3 cm in diameter.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.